Page last updated: 2024-10-26

diclofenac and Cardiovascular Diseases

diclofenac has been researched along with Cardiovascular Diseases in 60 studies

Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

ExcerptRelevanceReference
"A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA)."9.13Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). ( Curtis, S; Dore, R; Kaur, A; Krueger, K; Lino, L; Radominski, S; Simpson, R; Zhang, Y, 2008)
"To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib."9.12Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007)
" To compare the gastrointestinal (GI) tolerability, safety, and efficacy of etoricoxib and diclofenac in patients with osteoarthritis (OA)."9.12Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. ( Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B, 2007)
"OA patients initiating tramadol have an increased risk of mortality, VTE, and hip fractures within 1 year compared with commonly prescribed NSAIDs, but not with codeine."8.12Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study. ( Aviña-Zubieta, JA; Cibere, J; Esdaile, JM; Kopec, JA; Li, L; Lu, N; Marozoff, S; Xie, H, 2022)
"A previously healthy 60-year-old man receiving aspirin for primary prevention of cardiovascular disease presented with hemoptysis after 1 week of treatment for his back pain with diclofenac."7.77Hemoptysis under diclofenac and antiplatelet doses of aspirin. ( Yiannakopoulou, EC, 2011)
"We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily)."7.73Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Bolognese, JA; Bombardier, C; Cannon, CP; Curtis, SP; Erdmann, E; FitzGerald, GA; Kaur, A; Krum, H; Laine, L; Reicin, AS; van der Heijde, D; Weinblatt, ME, 2006)
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials."7.71Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002)
" Concerning duration, while the identification of a safe temporal window is less defined, some studies reported an absence or a very low risk when the exposure is shorter than 30 days."5.43Safety and efficacy of low doses of diclofenac on acute pain in the emergency setting. ( Capaldi, L; Di Leo, M; Franceschi, F; Gabrielli, M; Gilardi, E; Merra, G; Migneco, A; Ojetti, V; Petruzziello, C; Santarelli, L; Saviano, L, 2016)
"A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA)."5.13Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). ( Curtis, S; Dore, R; Kaur, A; Krueger, K; Lino, L; Radominski, S; Simpson, R; Zhang, Y, 2008)
" To compare the gastrointestinal (GI) tolerability, safety, and efficacy of etoricoxib and diclofenac in patients with osteoarthritis (OA)."5.12Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. ( Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B, 2007)
"To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib."5.12Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007)
" Keywords: nonsteroidal anti-inflammatory drugs, cardiovascular diseases, cardiovascular risk, lornoxicam, diclofenac sodium, thrombo-elastogram, myocardial infarction, stroke."5.01Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk. ( Khovasova, NO; Naumov, AV; Tkacheva, ON, 2019)
"Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis."4.80Celecoxib clinical profile. ( Tive, L, 2000)
" We used a Mantel-Haenszel method to obtain odds ratios (ORs) of the association between NSAID use (ibuprofen, naproxen, or diclofenac) and MACE (myocardial infarction, ischemic stroke, heart failure, or all-cause death)."4.31Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study. ( Bonnesen, K; Ehrenstein, V; Grønkjær, MS; Hallas, J; Lash, TL; Pedersen, L; Schmidt, M; Sørensen, HT, 2023)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."4.21 ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
"OA patients initiating tramadol have an increased risk of mortality, VTE, and hip fractures within 1 year compared with commonly prescribed NSAIDs, but not with codeine."4.12Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study. ( Aviña-Zubieta, JA; Cibere, J; Esdaile, JM; Kopec, JA; Li, L; Lu, N; Marozoff, S; Xie, H, 2022)
" As the model drug, we chose diclofenac because of its known high CV toxicity, as markers of CV risks, we assessed concentrations of cytochrome P450-mediated metabolites of arachidonic acid (ArA), and we used adjuvant arthritis as an experimental model of arthritis."3.91Dose-dependency of the cardiovascular risks of non-steroidal anti-inflammatory drugs. ( Ahmed, SA; Al-Lawati, H; Jamali, F, 2019)
"We evaluated 2-year CV outcomes in a prospective, nested biomarker study among patients (N = 6273) with rheumatoid arthritis and osteoarthritis treated with NSAID in the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) trial."3.77Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. ( Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT, 2011)
"A previously healthy 60-year-old man receiving aspirin for primary prevention of cardiovascular disease presented with hemoptysis after 1 week of treatment for his back pain with diclofenac."3.77Hemoptysis under diclofenac and antiplatelet doses of aspirin. ( Yiannakopoulou, EC, 2011)
" Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0."3.75Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009)
"To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population."3.74Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007)
"We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily)."3.73Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Bolognese, JA; Bombardier, C; Cannon, CP; Curtis, SP; Erdmann, E; FitzGerald, GA; Kaur, A; Krum, H; Laine, L; Reicin, AS; van der Heijde, D; Weinblatt, ME, 2006)
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials."3.71Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002)
" Data are limited regarding CV risks associated with short-term nonsteroidal anti-inflammatory drug use, including injectable formulations, although it has been suggested that even a single dose may increase CV adverse event (AE) risk."2.82Cardiovascular safety of hydroxypropyl-β-cyclodextrin-diclofenac in the management of acute postsurgical pain: a pooled analysis of 2 randomized, double-blind, placebo- and active comparator-controlled phase III clinical trials. ( Carr, DB; Daniels, SE; Gan, TJ; Lacouture, PG; Min, LH; Reyes, CR; Singla, N, 2016)
" The cumulative gastrointestinal (GI)/liver adverse events (AEs) discontinuation rate was significantly lower for etoricoxib than diclofenac in each patient cohort; HR (95% CI) of 0."2.74Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). ( Cannon, CP; Combe, B; Connors, L; Curtis, S; Emery, P; Kaur, A; Laine, L; McCarthy, T; McLay, J; Swergold, G; Zerbini, C, 2009)
"Among their beneficial effects, non-steroidal anti-inflammatory drugs may also exert several side effects which depend on the dosage and the type of these medications."2.52[Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous]. ( Horváth, VJ; Koós, CG; Lakatos, P; Putz, Z; Szabó, G; Tabák, GÁ, 2015)
"To our knowledge, this is the first study to quantify and aggregate the continuous relationship between the risk of GI or CV events and the dosage of an NSAID."2.50Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. ( Miles, L; Mladsi, DM; Odom, DM; Ronquest, N; Saag, KG; Sherif, BN; Wang, J, 2014)
"Naproxen was risk-neutral at all doses."2.47Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. ( Henry, D; McGettigan, P, 2011)
" Traditional NSAIDs are associated with an increased risk of serious gastrointestinal (GI) adverse events versus COX-2 selective inhibitors, and chronic use frequently necessitates adjunctive therapy with gastroprotective agents."2.44Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. ( Baraf, HS, 2007)
"Celecoxib was not associated with an elevated risk of vascular occlusion, summary relative risk 1."2.43Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. ( Henry, D; McGettigan, P, 2006)
"Diclofenac has increased cardiovascular risks, but its risk profile compared with other COX-2 inhibitors remains unknown."1.72Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials. ( Pedersen, L; Schmidt, M; Sørensen, HT, 2022)
" Concerning duration, while the identification of a safe temporal window is less defined, some studies reported an absence or a very low risk when the exposure is shorter than 30 days."1.43Safety and efficacy of low doses of diclofenac on acute pain in the emergency setting. ( Capaldi, L; Di Leo, M; Franceschi, F; Gabrielli, M; Gilardi, E; Merra, G; Migneco, A; Ojetti, V; Petruzziello, C; Santarelli, L; Saviano, L, 2016)
" The reference dose of Diclofenac used in all randomized controlled trials is 150 mg/die; this controlled release dosage allows to decrease the number of daily administrations, ensuring a better patient compliance, especially if elderly and/or in polytherapy."1.40[Diclofenac: update on tolerableness and spinal anti-inflammatory action]. ( Sandri, A, 2014)
" Despite the many available forms of NSAIDs, including injectable as well as topical, oral dosing is the most common route, usually the one route consistently associated with chronic use and thus the one that carries the most risk."1.39Nonsteroidal anti-inflammatory drugs and their risk: a story still in development. ( Simon, LS, 2013)
" Etoricoxib is partly metabolised by the cytochrome P450 isoenzyme CYP 3A4 and increases the bioavailability of ethinylestradiol."1.34Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain. ( , 2007)

Research

Studies (60)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's25 (41.67)29.6817
2010's27 (45.00)24.3611
2020's8 (13.33)2.80

Authors

AuthorsStudies
Li, L2
Marozoff, S1
Lu, N1
Xie, H1
Kopec, JA1
Cibere, J1
Esdaile, JM1
Aviña-Zubieta, JA1
Schmidt, M6
Sørensen, HT3
Pedersen, L3
Bonnesen, K1
Ehrenstein, V1
Grønkjær, MS1
Hallas, J3
Lash, TL1
Ernst, MT2
Pottegård, A3
Scholle, O1
Kollhorst, B1
Haug, U1
Moore, N2
Morales, DR1
Morant, SV1
MacDonald, TM2
Herings, RMC1
Smits, E1
Overbeek, JA1
Mackenzie, IS2
Doney, ASF1
Mitchell, L1
Bennie, M1
Robertson, C1
Wei, L2
Nicholson, L1
Morris, C1
Flynn, RWV1
Nese, M1
Riboli, G1
Brighetti, G1
Sassi, V1
Camela, E1
Caselli, G1
Sassaroli, S1
Borlimi, R1
Aucoin, M1
Cooley, K1
Saunders, PR1
Carè, J1
Anheyer, D1
Medina, DN1
Cardozo, V1
Remy, D1
Hannan, N1
Garber, A1
Velayos, M1
Muñoz-Serrano, AJ1
Estefanía-Fernández, K1
Sarmiento Caldas, MC1
Moratilla Lapeña, L1
López-Santamaría, M1
López-Gutiérrez, JC1
Li, J1
Zhang, J1
Shen, S1
Zhang, B2
Yu, WW1
Toyoda, H1
Huang, DQ1
Le, MH1
Nguyen, MH1
Huang, R1
Zhu, L1
Wang, J7
Xue, L1
Liu, L2
Yan, X2
Huang, S1
Li, Y6
Xu, T1
Li, C2
Ji, F1
Ming, F1
Zhao, Y2
Cheng, J1
Wang, Y3
Zhao, H1
Hong, S1
Chen, K2
Zhao, XA1
Zou, L1
Sang, D1
Shao, H1
Guan, X1
Chen, X2
Chen, Y4
Wei, J1
Zhu, C1
Wu, C1
Moore, HB1
Barrett, CD1
Moore, EE1
Jhunjhunwala, R1
McIntyre, RC1
Moore, PK1
Hajizadeh, N1
Talmor, DS1
Sauaia, A1
Yaffe, MB1
Liu, C3
Lin, Y1
Dong, Y1
Wu, Y1
Bao, Y1
Yan, H2
Ma, J1
Fernández-Cuadros, ME1
Albaladejo-Florín, MJ1
Álava-Rabasa, S1
Usandizaga-Elio, I1
Martinez-Quintanilla Jimenez, D1
Peña-Lora, D1
Neira-Borrajo, I1
López-Muñoz, MJ1
Rodríguez-de-Cía, J1
Pérez-Moro, OS1
Abdallah, M1
Alsaleh, H1
Baradwan, A1
Alfawares, R1
Alobaid, A1
Rasheed, A1
Soliman, I1
Wendel Garcia, PD1
Fumeaux, T1
Guerci, P1
Heuberger, DM1
Montomoli, J2
Roche-Campo, F1
Schuepbach, RA1
Hilty, MP1
Poloni, TE1
Carlos, AF1
Cairati, M1
Cutaia, C1
Medici, V1
Marelli, E1
Ferrari, D1
Galli, A1
Bognetti, P1
Davin, A1
Cirrincione, A1
Ceretti, A1
Cereda, C1
Ceroni, M1
Tronconi, L1
Vitali, S1
Guaita, A1
Leeds, JS1
Raviprakash, V1
Jacques, T1
Scanlon, N1
Cundall, J1
Leeds, CM1
Riva, A1
Gray, EH1
Azarian, S1
Zamalloa, A1
McPhail, MJW1
Vincent, RP1
Williams, R1
Chokshi, S1
Patel, VC1
Edwards, LA1
Alqarawi, W1
Birnie, DH1
Golian, M1
Nair, GM1
Nery, PB1
Klein, A1
Davis, DR1
Sadek, MM1
Neilipovitz, D1
Johnson, CB1
Green, MS1
Redpath, C1
Miller, DC1
Beamer, P1
Billheimer, D1
Subbian, V1
Sorooshian, A1
Campbell, BS1
Mosier, JM1
Novaretti, JV1
Astur, DC1
Cavalcante, ELB1
Kaleka, CC1
Amaro, JT1
Cohen, M1
Huang, W1
Li, T1
Ling, Y1
Qian, ZP1
Zhang, YY1
Huang, D1
Xu, SB1
Liu, XH1
Xia, L1
Yang, Y3
Lu, SH1
Lu, HZ1
Zhang, R2
Ma, JX1
Tang, S1
Li, CM1
Wan, J1
Wang, JF1
Ma, JQ1
Luo, JJ1
Chen, HY2
Mi, SL1
Chen, SY1
Su, YG1
Ge, JB1
Milheiro, SA1
Gonçalves, J1
Lopes, RMRM1
Madureira, M1
Lobo, L1
Lopes, A1
Nogueira, F1
Fontinha, D1
Prudêncio, M1
M Piedade, MF1
Pinto, SN1
Florindo, PR1
Moreira, R1
Castillo-Lora, J1
Delley, MF1
Laga, SM1
Mayer, JM1
Sutjarit, N1
Thongon, N1
Weerachayaphorn, J1
Piyachaturawat, P1
Suksamrarn, A1
Suksen, K1
Papachristou, DJ1
Blair, HC1
Hu, Y1
Shen, P1
Zeng, N1
Wang, L3
Yan, D1
Cui, L1
Yang, K2
Zhai, C1
Yang, M1
Lao, X1
Sun, J1
Ma, N1
Wang, S1
Ye, W1
Guo, P1
Rahimi, S1
Singh, MP1
Gupta, J1
Nakanishi, I1
Ohkubo, K1
Shoji, Y1
Fujitaka, Y1
Shimoda, K1
Matsumoto, KI1
Fukuhara, K1
Hamada, H1
van der Boom, T1
Gruppen, EG1
Lefrandt, JD1
Connelly, MA1
Links, TP1
Dullaart, RPF1
Berry, JD1
Bedlack, R1
Mathews, D1
Agnese, W1
Apple, S1
Meloncelli, S1
Divizia, M1
Germani, G1
Adefegha, SA1
Bottari, NB1
Leal, DB1
de Andrade, CM1
Schetinger, MR1
Martínez-Velasco, A1
Perez-Ortiz, AC1
Antonio-Aguirre, B1
Martínez-Villaseñor, L1
Lira-Romero, E1
Palacio-Pastrana, C1
Zenteno, JC1
Ramirez, I1
Zepeda-Palacio, C1
Mendoza-Velásquez, C1
Camacho-Ordóñez, A1
Ortiz Bibriesca, DM1
Estrada-Mena, FJ1
Martin, BL1
Thompson, LC1
Kim, YH2
Snow, SJ1
Schladweiler, MC1
Phillips, P1
Harmon, M1
King, C1
Richards, J1
George, I1
Haykal-Coates, N1
Gilmour, MI1
Kodavanti, UP1
Hazari, MS1
Farraj, AK1
Shen, Z1
Zou, Y1
Gao, K1
Lazar, S1
Wurtzel, JGT1
Ma, P1
Goldfinger, LE1
Vukelic, M1
Laloo, A1
Kyttaris, VC1
Chen, R1
Chen, J2
Xun, J1
Hu, Z1
Huang, Q2
Steinhart, C1
Shen, Y1
Lu, H1
Mansuri, A1
Lokhande, K1
Kore, S1
Gaikwad, S1
Nawani, N1
Swamy, KV1
Junnarkar, M1
Pawar, S1
Shaheen, MY1
Basudan, AM1
Niazy, AA1
van den Beucken, JJJP1
Jansen, JA1
Alghamdi, HS1
Gao, Q2
Guo, X1
Cao, Y1
Jia, X1
Xu, S1
Lu, C2
Zhu, H2
Melku, M1
Abebe, G1
Teketel, A1
Asrie, F1
Yalew, A1
Biadgo, B1
Kassa, E1
Damtie, D1
Anlay, DZ1
Ahmed, MFE1
Ramadan, H1
Seinige, D1
Kehrenberg, C1
Abd El-Wahab, A1
Volkmann, N1
Kemper, N1
Schulz, J1
Hu, MY1
Wu, YN1
McEvoy, MP1
Wang, YF1
Cong, WL1
Liu, LP1
Li, XX1
Zhou, CL1
Chen, WM1
Wei, KL1
Tung, SY1
Shen, CH1
Chang, TS1
Yen, CW1
Hsieh, YY1
Chiu, WN1
Hu, JH1
Lu, SN1
Hung, CH1
Alakavuklar, MA1
Fuqua, C1
Luo, KL1
Underwood, RS1
Greenwald, I1
Elashiry, MM1
Elashiry, M1
Zeitoun, R1
Elsayed, R1
Tian, F1
Saber, SE1
Elashry, SH1
Tay, FR1
Cutler, CW1
O'Dowd, A1
Maciel, M1
Poole, ST1
Jobling, MG1
Rollenhagen, JE1
Woods, CM1
Sincock, SA1
McVeigh, AL1
Gregory, MJ1
Maves, RC1
Prouty, MG1
Holmes, RK1
Savarino, SJ1
Mor, MK1
Palevsky, PM1
Kaufman, JS1
Thiessen Philbrook, H1
Weisbord, SD1
Parikh, CR1
John, CM1
Phillips, NJ1
Jarvis, GA1
Zhu, Y1
Kilburn, S1
Kapoor, M1
Chaturvedi, S1
Shaw, KJ1
Chaturvedi, V1
Kong, X1
Zhang, T1
Xiao, H1
Feng, X1
Tu, H1
Feng, J1
Sabet, M1
Tarazi, Z1
Griffith, DC1
Nguyen, F1
Guan, P1
Guerrero, DT1
Kolla, V1
Naraparaju, K1
Perry, LM1
Soberman, D1
Pressly, BB1
Alferiev, IS1
Chorny, M1
Brodeur, GM1
Gao, X2
Cheng, YH1
Enten, GA1
DeSantis, AJ1
Gaponenko, V1
Majetschak, M1
Kim, DY1
Choi, MJ1
Ko, TK1
Lee, NH1
Kim, OH1
Cheon, HG1
Cai, H1
Yip, V1
Lee, MV1
Wong, S1
Saad, O1
Ma, S1
Ljumanovic, N1
Khojasteh, SC1
Kamath, AV1
Shen, BQ1
Cuypers, ML1
Chanteux, H1
Gillent, E1
Bonnaillie, P1
Saunders, K1
Beckers, C1
Delatour, C1
Dell'Aiera, S1
Ungell, AL1
Nicolaï, J1
Knapp, AK1
Chen, A1
Griffin-Nolan, RJ1
Baur, LE1
Carroll, CJW1
Gray, JE1
Hoffman, AM1
Li, X4
Post, AK1
Slette, IJ1
Collins, SL1
Luo, Y1
Smith, MD1
Temitayo, GI1
Olawande, B1
Emmanuel, YO1
Timothy, AT1
Kehinde, O1
Susan, LF1
Ezra, L1
Joseph, OO1
Lev, S1
Desmarini, D1
Liuwantara, D1
Sorrell, TC1
Hawthorne, WJ1
Djordjevic, JT1
Verso, MG1
Costantino, C1
Marrella, A1
Immordino, P1
Vitale, F1
Amodio, E1
Wang, YD1
Yao, WL1
Xin, ZM1
Han, TT1
Wang, ZG1
Chen, L1
Cai, C1
Zhang, Y5
Ba, D1
Wen, S1
Tian, Q1
Lv, W1
Cheng, G1
Li, N1
Yue, XY1
Chu, WJ1
Chen, Q1
Choi, ES1
Zhao, X3
Zhou, HD1
Sun, XF1
Sharma, S2
Chhoker, S1
Xie, C1
Ong, EWY1
Tan, ZK1
Evans, S1
Weinheimer, CJ1
Kovacs, A1
Williams, JW1
Randolph, GJ1
Jiang, W1
Barger, PM1
Mann, DL1
Liu, J2
Huang, Y1
Kong, L1
Yu, X1
Feng, B1
Liu, D1
Zhao, B1
Mendes, GC1
Yuan, P1
Ge, D1
Wang, WM1
Fontes, EPB1
Li, P1
Shan, L1
He, P1
Katoh, T1
Sengoku, T1
Hirata, K1
Ogata, K1
Suga, H1
Shun, C1
Yong-Yi, J1
Mei-Li, C1
Shi-Li, L1
Jian-Bo, Z1
Dan-Li, W1
Zhi-Min, G1
Ibrahim, AM1
Zakhary, SY1
Amin, SAW1
Ugurlu, M1
Fornari, VJ1
Hartmann, MSM1
Vanni, JR1
Rodriguez, R1
Langaro, MC1
Pelepenko, LE1
Zaia, AA1
Nakanjako, D1
Zalwango, F1
Wairagala, P1
Luboga, F1
Andia Biraro, I1
Bukirwa, VD1
Mboowa, MG1
Cose, S1
Seeley, J1
Elliott, A1
Zhao, G1
Sun, P1
Hao, S1
Wang, X1
Qu, G1
Xing, Y1
Xu, X1
Maierhofer, M1
Rieger, V1
Mayr, T1
Liu, Y2
Zhang, Q1
Bigliardi, AP1
Fernandes, CLF1
Pinto, EA1
Dos Santos, M1
Garcia, EM1
Baisch, PRM1
Soares, MCF1
Muccillo-Baisch, AL1
da Silva Júnior, FMR1
Yu, W1
Ju, C1
Wang, K1
Zheng, Z1
Liu, H1
Gao, Y1
Martínez-Navarro, EM1
Cebrián-Tarancón, C1
Moratalla-López, N1
Lorenzo, C1
Alonso, GL1
Salinas, RM1
Bermúdez de Castro, JM1
Modesto-Mata, M1
Martín-Francés, L1
García-Campos, C1
Martínez de Pinillos, M1
Martinón-Torres, M1
Hasani, M1
Wu, F2
Warriner, K1
Kurz, M1
Gretzke, D1
Hörlein, R1
Turpault, S1
Atzrodt, J1
Derdau, V1
Yao, Y1
Ou, X1
Zhao, S1
Tian, B1
Jin, S1
Jiang, Z1
Zhou, Z1
Liu, M2
Jiang, GD1
Mou, LH1
Chen, JJ1
Li, ZY1
He, SG1
Reale, E1
Fustinoni, S1
Mercadante, R1
Polledri, E1
Hopf, NB1
Grant, PC1
Levy, K1
Lattimer, TA1
Depner, RM1
Kerr, CW1
Sato, J1
Merenda, MEZ1
Uemoto, AT1
Dos Santos, MP1
Barion, MRL1
Carciofi, AC1
de Paula Dorigam, JC1
Ribeiro, LB1
Vasconcellos, RS1
Waller, SB1
Peter, CM1
Hoffmann, JF1
Cleff, MB1
Faria de, RO1
Zani, JL1
Martins, BA1
Sande, D1
Solares, MD1
Takahashi, JA1
Yang, S2
Jia, Y1
Yin, C1
Zhao, R1
Ojha, M1
Wu, B1
Deepa, M1
Mo, J1
Au, DW1
Wan, MT1
Shi, J1
Zhang, G1
Winkler, C1
Kong, RY1
Seemann, F1
Bianco, M1
Calvano, CD1
Ventura, G1
Bianco, G1
Losito, I1
Cataldi, TRI1
Angiolella, L1
Staudt, A1
Duarte, PF1
Amaral, BPD1
Peixoto Andrade, BCO1
Simas, NK1
Correa Ramos Leal, I1
Sangenito, LS1
Santos, ALSD1
de Oliveira, D1
Junges, A1
Cansian, RL1
Paroul, N1
Siu, J1
Klingler, L1
Hung, CT1
Jeong, SH1
Smith, S1
Tingle, MD1
Wagner Mackenzie, B1
Biswas, K1
Douglas, RG1
Oza, AM1
Lorusso, D1
Aghajanian, C1
Oaknin, A1
Dean, A1
Colombo, N1
Weberpals, JI1
Clamp, AR1
Scambia, G1
Leary, A1
Holloway, RW1
Gancedo, MA1
Fong, PC1
Goh, JC1
O'Malley, DM1
Armstrong, DK1
Banerjee, S1
García-Donas, J1
Swisher, EM1
Cella, D1
Meunier, J1
Goble, S1
Cameron, T1
Maloney, L1
Mörk, AC1
Bedel, J1
Ledermann, JA1
Coleman, RL1
Vlek, SL1
Burm, R1
Govers, TM1
Vleugels, MPH1
Tuynman, JB1
Mijatovic, V1
Leicht, AS1
Connor, J1
Conduit, N1
Vaquera, A1
Gómez, MA1
McKay, JA1
Church, AL1
Rubin, N1
Emory, TH1
Hoven, NF1
Kuehn-Hajder, JE1
Nelson, MT1
Ramanna, S1
Auerbach, EJ1
Moeller, S1
Bolan, PJ1
Fox, NP1
Leonard, M1
Sjerps, MJ1
Chang, EF1
Hyun, S1
Saejio, A1
Shanmugam, S1
Liu, X1
Sun, M1
Bai, Z1
Jaque-Fernandez, F1
Beaulant, A1
Berthier, C1
Monteiro, L1
Allard, B1
Casas, M1
Rieusset, J1
Jacquemond, V1
Góngora-García, OR1
Aca-Aca, G1
Baz-Rodríguez, SA1
Monte, A1
Maganaris, C1
Baltzopoulos, V1
Zamparo, P1
Wang, Z2
Hou, Y1
Cai, L1
Tu, YJ1
Tan, B1
Jiang, L1
Wu, ZH1
Yu, HJ1
Li, XQ1
Yang, AD1
Titze, IR1
Palaparthi, A1
Mau, T1
González, MA1
Goiri, F1
Barandika, JF1
García-Pérez, AL1
Jatt, LP1
Gandhi, MM1
Guo, R1
Sukhija-Cohen, A1
Bhattacharya, D1
Tseng, CH1
Chew, KW1
Onwumere, J1
Pia Tek, J1
Budnyak, T1
Budnyk, S1
Karim, Z1
Thersleff, T1
Kuśtrowski, P1
Mathew, AP1
Slabon, A1
Guo, M1
Zhao, T1
Xing, Z1
Qiu, Y1
Pan, K1
Li, Z2
Zhou, W1
Ghassemi Tabrizi, S1
Arbuznikov, AV1
Jiménez-Hoyos, CA1
Kaupp, M1
Lin, MH2
Bulman, DM1
Remucal, CK1
Chaplin, BP1
Laguerre, A1
George, LA1
Gall, ET1
Emerson, MS1
Wang, H3
Maginn, EJ1
Margulis, CJ1
Li, H2
Feng, W1
Kang, X2
Yan, S1
Chao, M1
Mo, S1
Sun, W1
Lu, Y1
Chen, C1
Stevens, DM1
Adiseshaiah, P1
Dasa, SSK1
Potter, TM1
Skoczen, SL1
Snapp, KS1
Cedrone, E1
Patel, N1
Busman-Sahay, K1
Rosen, EP1
Sykes, C1
Cottrell, M1
Dobrovolskaia, MA1
Estes, JD1
Kashuba, ADM1
Stern, ST1
Özütemiz, C1
Neil, EC1
Tanwar, M1
Rubin, NT1
Ozturk, K1
Cayci, Z1
Duscha, BD1
Kraus, WE1
Jones, WS1
Robbins, JL1
Piner, LW1
Huffman, KM1
Allen, JD1
Annex, BH1
Mehmood, T1
Ahmad, I1
Bibi, S1
Mustafa, B1
Ali, I1
Dahal, RH1
Chaudhary, DK1
Kim, DU1
Kim, J1
Yeter, HH1
Gonul, I1
Guz, G1
Helvaci, O1
Korucu, B1
Akcay, OF1
Derici, U1
Arinsoy, T1
Neffati, R1
Judeinstein, P1
Rault, J1
Xu, Y1
Chai, X1
Ren, T1
Yu, S1
Fu, Q2
Ye, J1
Ge, X1
Song, J1
Yang, H2
El-Baba, TJ1
Lutomski, CA1
Kantsadi, AL1
Malla, TR1
John, T1
Mikhailov, V1
Bolla, JR1
Schofield, CJ1
Zitzmann, N1
Vakonakis, I1
Robinson, CV1
Langham, MC1
Caporale, AS1
Wehrli, FW1
Parry, S1
Schwartz, N1
den Boer, RB1
Jones, KI1
Ash, S1
van Boxel, GI1
Gillies, RS1
O'Donnell, T1
Ruurda, JP1
Sgromo, B1
Silva, MA1
Maynard, ND1
Sivieri, EM1
Eichenwald, EC1
Rub, D1
Abbasi, S1
Krahnert, I1
Bolze, A1
Gibon, Y1
Fernie, AR1
Huang, L1
Wan, Y1
Dang, Z1
Yang, P1
Yang, Q1
Wu, S2
Lin, CC1
Hsu, CT1
Liu, W2
Huang, SC1
Kortz, U1
Mougharbel, AS1
Chen, TY1
Hu, CW1
Lee, JF1
Wang, CC1
Liao, YF1
Li, LJ1
Peng, S1
Stimming, U1
Hebbar Kannur, K1
Yaqub, TB1
Pupier, C1
Héau, C1
Cavaleiro, A1
Yamamoto, S1
Ono, A1
Matsui, J1
Hoshino, N1
Akutagawa, T1
Miyashita, T1
Mitsuishi, M1
Patel, SM1
Smith, TG1
Morton, M1
Stiers, KM1
Seravalli, J1
Mayclin, SJ1
Edwards, TE1
Tanner, JJ1
Becker, DF1
Butcher, TW1
Yang, JL1
Hartwig, JF1
Yu, MF1
Xia, ZZ1
Yao, JC1
Feng, Z1
Li, DH1
Liu, T1
Cheng, GJ1
He, DL1
Li, XH1
Huurman, R1
Schinkel, AFL1
de Jong, PL1
van Slegtenhorst, MA1
Hirsch, A1
Michels, M1
Kataja, A1
Tarvasmäki, T1
Lassus, J1
Sionis, A1
Mebazaa, A1
Pulkki, K1
Banaszewski, M1
Carubelli, V1
Hongisto, M1
Jankowska, E1
Jurkko, R1
Jäntti, T1
Kasztura, M1
Parissis, J1
Sabell, T1
Silva-Cardoso, J1
Spinar, J1
Tolppanen, H1
Harjola, VP1
Carsetti, A1
Damiani, E1
Casarotta, E1
Scorcella, C1
Domizi, R1
Gasparri, F1
Gabbanelli, V1
Pantanetti, S1
Carozza, R1
Adrario, E1
Donati, A1
Almada, E1
Pariani, A1
Rivabella Maknis, T1
Hidalgo, F1
Vena, R1
Favre, C1
Larocca, MC1
Lu, ZY1
Jiang, WD1
Wu, P1
Kuang, SY1
Tang, L1
Yang, J1
Zhou, XQ1
Feng, L1
Leal, M1
Zampini, IC1
Mercado, MI1
Moreno, MA1
Simirgiotis, MJ1
Bórquez, J1
Ponessa, G1
Isla, MI1
Saliu, IO1
Amoo, ZA1
Khan, MF1
Olaleye, MT1
Rema, V1
Akinmoladun, AC1
Khan, AU1
Rahman, AU1
Yuan, Q1
Ahmad, A1
Khan, ZUH1
Mahnashi, MH1
Alyami, BA1
Alqahtani, YS1
Ullah, S1
Wirman, AP1
Gao, M1
Deng, L1
Zhang, K1
Wang, M1
Xia, Z1
Gao, D1
Balkissou, AD1
Poka-Mayap, V1
Massongo, M1
Djenabou, A1
Endale-Mangamba, LM1
Olomo, EJ1
Boulleys-Nana, JR1
Diffo-Sonkoue, L1
Adidigue-Ndiome, R1
Alexandra, AJE1
Haman-Wabi, AB1
Adama, S1
Iddi-Faical, A1
Pefura-Yone, EW1
Zhao, Q1
Tong, W1
Ge, C1
Zhao, D1
Norbäck, D1
Li, B1
Zhao, Z1
Huang, C1
Zhang, X1
Qian, H1
Yang, X1
Sun, Y1
Sundell, J1
Deng, Q1
Kim, HJ1
Jeon, JW1
Hwang, SM1
Chu, KI1
Cha, YH1
Kwak, YD1
Choi, SD1
Aslam, M1
Kim, CG1
Zhou, J1
Yang, E1
Yang, W1
Kristensen, KB1
Karlstad, Ø1
Martikainen, JE1
Wastesson, JW1
Zoega, H1
Naumov, AV1
Tkacheva, ON1
Khovasova, NO1
Ahmed, SA1
Al-Lawati, H1
Jamali, F1
Spitz, S1
Dickson, RC1
Soubrier, M1
Rosenbaum, D1
Tatar, Z1
Lahaye, C1
Dubost, JJ1
Mathieu, S1
Sifferlin, A1
Salvo, F1
Duong, M1
Blin, P1
Pariente, A1
Simon, LS1
Harbin, M1
Turgeon, RD1
Kolber, MR1
Odom, DM1
Mladsi, DM1
Saag, KG1
Sherif, BN1
Miles, L1
Ronquest, N1
Sandri, A1
Horváth, VJ1
Tabák, GÁ1
Szabó, G1
Putz, Z1
Koós, CG1
Lakatos, P1
Ungprasert, P1
Zolotovskaya, IA1
Davydkin, IL1
Gan, TJ1
Singla, N1
Daniels, SE1
Lacouture, PG1
Min, LH1
Reyes, CR1
Carr, DB1
Franceschi, F1
Saviano, L1
Petruzziello, C1
Gabrielli, M1
Santarelli, L1
Capaldi, L1
Di Leo, M1
Migneco, A1
Gilardi, E1
Merra, G1
Ojetti, V1
Fosbøl, EL1
Torp-Pedersen, C1
Olsen, AS1
Christensen, B1
Gislason, GH1
Combe, B1
Swergold, G1
McLay, J1
McCarthy, T1
Zerbini, C1
Emery, P1
Connors, L1
Kaur, A5
Curtis, S2
Laine, L3
Cannon, CP3
Ray, WA1
Varas-Lorenzo, C2
Chung, CP1
Castellsague, J2
Murray, KT1
Stein, CM1
Daugherty, JR1
Arbogast, PG1
García-Rodríguez, LA1
Rovati, GE1
Sala, A1
Capra, V1
Dahlén, SE1
Folco, G1
Yiannakopoulou, EC1
Ruff, CT1
Morrow, DA1
Jarolim, P1
Ren, F1
Contant, CF1
Curtis, SP3
Brune, K1
McGettigan, P2
Henry, D2
Peniston, JH1
Gold, MS1
Wieman, MS1
Alwine, LK1
Doggrell, SA1
Matchaba, P1
Gitton, X1
Krammer, G1
Ehrsam, E1
Sloan, VS1
Olson, M1
Mellein, B2
Hoexter, G1
Orloff, J1
Garaud, JJ1
Rosenberg, JA1
Goldstein, JL1
Maguire, A1
Perez-Gutthann, S1
Marwali, MR1
Mehta, JL1
Sibilia, J1
Deray, G2
Montalescot, G1
Valat, JP1
Héloire, F1
Rodríguez, LA1
Patrignani, P1
FitzGerald, GA1
Krum, H1
Bolognese, JA1
Reicin, AS2
Bombardier, C1
Weinblatt, ME1
van der Heijde, D1
Erdmann, E1
Psaty, BM1
Weiss, NS1
Baraf, HS2
Fuentealba, C1
Greenwald, M1
Brzezicki, J1
O'Brien, K1
Soffer, B1
Polis, A1
Bird, S1
Farkouh, ME1
Greenberg, JD1
Jeger, RV1
Ramanathan, K1
Verheugt, FW1
Chesebro, JH1
Kirshner, H1
Hochman, JS1
Lay, CL1
Ruland, S1
Matchaba, PT1
Fuster, V1
Abramson, SB1
Einecke, D1
Krüger, K1
Bannwarth, B1
Bérenbaum, F1
Krueger, K1
Lino, L1
Dore, R1
Radominski, S1
Simpson, R1
Hennekens, CH1
Borzak, S1
Fleischmann, R1
Tannenbaum, H1
Patel, NP1
Notter, M1
Sallstig, P1
Reginster, JY1
Tive, L1
Shapiro, D1
Sperling, RS1
Barr, E1
Yu, Q1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Chronic Pain Relief Over Knee Joint Area by Gua Sha Therapy[NCT03821194]40 participants (Anticipated)Interventional2019-01-25Recruiting
A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445]Phase 323,498 participants (Actual)Interventional2003-01-31Completed
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073]Phase 2/Phase 384 participants (Actual)Interventional2017-04-04Completed
A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703]Phase 36,000 participants Interventional2002-06-27Completed
A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis[NCT00092742]Phase 34,086 participants (Actual)Interventional2003-02-28Completed
A Single Center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain.[NCT01619150]Phase 239 participants (Actual)Interventional2012-07-31Completed
A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in [NCT00145301]Phase 33,036 participants Interventional2004-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

19 reviews available for diclofenac and Cardiovascular Diseases

ArticleYear
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
    Drug safety, 2020, Volume: 43, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Cardiovascular Diseases; Cyclooxygenase 2 I

2020
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk.
    Terapevticheskii arkhiv, 2019, Mar-11, Volume: 91, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclo

2019
Vascular effects of nonsteroidal antiinflammatory drugs.
    Joint bone spine, 2013, Volume: 80, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diclofenac; Humans; Napro

2013
Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:2

    Topics: Cardiovascular Diseases; Diclofenac; Humans; Ibuprofen; Nonprescription Drugs; Risk Factors

2014
Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews.
    Clinical therapeutics, 2014, Jun-01, Volume: 36, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Dose-Response Relation

2014
[Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous].
    Orvosi hetilap, 2015, Mar-29, Volume: 156, Issue:13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cardiovascular System; Di

2015
[Cardiovascular risks of non-steroidal anti-inflammatory drugs treatment].
    Ugeskrift for laeger, 2016, Dec-26, Volume: 178, Issue:52

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Blood Pressure; Cardiovascular Disease

2016
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.
    PLoS medicine, 2011, Volume: 8, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Humans; Ibuprofen; Nap

2011
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Cyclo

2013
The safety of lumiracoxib when used in the treatment of arthritis.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:2

    Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Org

2005
Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Clinical therapeutics, 2005, Volume: 27, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygen

2005
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
    JAMA, 2006, Oct-04, Volume: 296, Issue:13

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi

2006
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
    Thrombosis and haemostasis, 2006, Volume: 96, Issue:4

    Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inh

2006
[What do we know about the cardiovascular toxicity of the NSAIDs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco

2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas

2006
Lumiracoxib in the management of osteoarthritis and acute pain.
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:10

    Topics: Acute Disease; Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Appro

2007
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
    Current pharmaceutical design, 2007, Volume: 13, Issue:22

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Dis

2007
Celecoxib clinical profile.
    Rheumatology (Oxford, England), 2000, Volume: 39 Suppl 2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec

2000

Trials

11 trials available for diclofenac and Cardiovascular Diseases

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
[Effect of nonsteroidal anti-inflammatory drugs on the indicators of cardiovascular risk in patients with acute nonspecific back pain].
    Terapevticheskii arkhiv, 2015, Volume: 87, Issue:12

    Topics: Acute Pain; Aged; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Cardiovascular Diseases; Cyclo

2015
Cardiovascular safety of hydroxypropyl-β-cyclodextrin-diclofenac in the management of acute postsurgical pain: a pooled analysis of 2 randomized, double-blind, placebo- and active comparator-controlled phase III clinical trials.
    Journal of clinical anesthesia, 2016, Volume: 31

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Acute Pain; Adolescent; Adult; Aged; Anti-Inflammatory Agents, No

2016
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:4

    Topics: Aged; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Emergenci

2009
Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Cyclo

2013
Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities.
    Clinical interventions in aging, 2012, Volume: 7

    Topics: Administration, Cutaneous; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardio

2012
Safety and efficacy of lumiracoxib compared with NSAIDs.
    Nature clinical practice. Gastroenterology & hepatology, 2005, Volume: 2, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Double-Blind Method; D

2005
Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
    The Journal of rheumatology, 2007, Volume: 34, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Diclofe

2007
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Annals of the rheumatic diseases, 2007, Volume: 66, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 In

2007
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
    Annals of the rheumatic diseases, 2008, Volume: 67, Issue:3

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiova

2008
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
    BMC musculoskeletal disorders, 2008, Mar-07, Volume: 9

    Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury

2008

Other Studies

32 other studies available for diclofenac and Cardiovascular Diseases

ArticleYear
Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study.
    Arthritis research & therapy, 2022, 04-11, Volume: 24, Issue:1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Codeine; Cohort Studies; Cyc

2022
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials.
    Drug safety, 2022, Volume: 45, Issue:9

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2

2022
Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study.
    Drug safety, 2023, Volume: 46, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cross-Over Studies; Diclofe

2023
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
    European heart journal. Cardiovascular pharmacotherapy, 2023, 09-20, Volume: 9, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort Studies; Diclofenac; Heart

2023
Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis.
    Journal of internal medicine, 2020, Volume: 287, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Contraindications, Dr

2020
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:3

    Topics: Cardiovascular Diseases; Diclofenac; England; Europe; Humans; Interrupted Time Series Analysis; Neth

2021
Diclofenac use and cardiovascular risks: series of nationwide cohort studies.
    BMJ (Clinical research ed.), 2018, Sep-04, Volume: 362

    Topics: Acetaminophen; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort

2018
Nonaspirin Nonsteroidal Antiinflammatory Drug Use in the Nordic Countries from a Cardiovascular Risk Perspective, 2000-2016: A Drug Utilization Study.
    Pharmacotherapy, 2019, Volume: 39, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular

2019
Dose-dependency of the cardiovascular risks of non-steroidal anti-inflammatory drugs.
    Inflammopharmacology, 2019, Volume: 27, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arthritis, Experimental; Cardiov

2019
Remove diclofenac from lists of essential drugs.
    BMJ (Clinical research ed.), 2013, Feb-20, Volume: 346

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Drugs, Essential; Glob

2013
Physicians should be cautious when prescribing diclofenac.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Apr-02, Volume: 185, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Drug and Narcotic Cont

2013
Not all diclofenac is equal.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, May-14, Volume: 185, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cross Infection; Diclofenac; Enter

2013
More pain for painkillers.
    Time, 2013, Jun-24, Volume: 181, Issue:24

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase

2013
Nonsteroidal anti-inflammatory drugs and their risk: a story still in development.
    Arthritis research & therapy, 2013, Volume: 15 Suppl 3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Arthritis, Rheumatoid; Cardiovascular Diseases;

2013
Cardiovascular safety of NSAIDs.
    Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclo

2014
[Diclofenac: update on tolerableness and spinal anti-inflammatory action].
    Minerva medica, 2014, Volume: 105, Issue:4

    Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood-Brain Barrier; Car

2014
NSAIDs and cardiovascular disease: time to say no to diclofenac.
    Internal and emergency medicine, 2016, Volume: 11, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Humans

2016
NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
    Prescrire international, 2016, Volume: 25, Issue:167

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclo

2016
Safety and efficacy of low doses of diclofenac on acute pain in the emergency setting.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:20

    Topics: Acute Pain; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Humans; Ri

2016
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C

2009
Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk.
    Trends in pharmacological sciences, 2010, Volume: 31, Issue:3

    Topics: Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Endothelium, Vascular; Hu

2010
Hemoptysis under diclofenac and antiplatelet doses of aspirin.
    Pharmacology, 2011, Volume: 87, Issue:1-2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Back Pain; Cardiovascular Diseases; Diclofenac; Dr

2011
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
    The Journal of rheumatology, 2011, Volume: 38, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein

2011
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D

2007
The ever growing story of cyclo-oxygenase inhibition.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Cyclooxygenase Inhibito

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Lancet (London, England), 2006, Nov-18, Volume: 368, Issue:9549

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclo

2006
NSAID trials and the choice of comparators--questions of public health importance.
    The New England journal of medicine, 2007, Jan-25, Volume: 356, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials, Phase IV as Topic

2007
[Coronary risks with NSAID and coxibs. The end of hysteria].
    MMW Fortschritte der Medizin, 2006, Nov-30, Volume: 148, Issue:48

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause

2006
[3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    MMW Fortschritte der Medizin, 2006, Nov-30, Volume: 148, Issue:48

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygen

2006
Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire international, 2007, Volume: 16, Issue:92

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Clinical

2007
Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
    Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy

2008
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    The American journal of cardiology, 2002, Jan-15, Volume: 89, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T

2002